Simplexvirus (HSV) Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Simplexvirus (HSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Herpes simplex virus (HSV) infections, also known as simplexvirus infections, are caused by two types of viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, manifesting as cold sores around the mouth, while HSV-2 is primarily responsible for genital herpes. However, both types can cause infections in either location. These infections are highly contagious and transmitted through direct contact with an infected individual, especially during active outbreaks. The primary infection often occurs during childhood or adolescence, with the virus establishing lifelong latency in nerve cells after the initial outbreak. The virus may periodically reactivate, causing recurrent outbreaks, which are characterized by the appearance of sores, blisters, or ulcers in the affected area. Recurrences can be triggered by factors such as stress, illness, sun exposure, hormonal changes, or a weakened immune system.
HSV infections can have emotional and psychological impacts due to the stigma associated with the condition. Seeking support from healthcare professionals and support groups can be beneficial in managing the psychological aspects of living with herpes. Regular monitoring and managing triggers can aid in reducing the frequency and severity of outbreaks, improving the quality of life for individuals affected by HSV infections.
The Simplexvirus (HSV) Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Simplexvirus (HSV) Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Simplexvirus (HSV) Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 78 molecules, with 66 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Simplexvirus (HSV) Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Simplexvirus (HSV) Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Simplexvirus (HSV) Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AiCuris Anti-infective Cures AGApplied Research using OMIC Sciences SL
Assembly Biosciences Inc
Asterivir SA
Auritec Pharmaceuticals Inc
Auro Vaccines LLC
Beijing Kawin Technology Share-Holding Co Ltd
Biomere LLC
BioNTech SE
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
Casterbridge Pharmaceuticals Inc
Dultech Advanced Sciences
Erasmus MC
Eurocine Vaccines AB
Excell Biotech LLC
Excision BioTherapeutics Inc
Galenbio Ltd
German Cancer Research Center
GSK plc
Heidelberg Immunotherapeutics Gmbh
HSF Pharmaceuticals SA
Huinuo Biomedical Technology Co Ltd
Immune Modulation Inc
Innovative Molecules Gmbh
Jagiellonian University
Johns Hopkins University
Johnson & Johnson
Kexing Biopharm Co Ltd
Mapp Biopharmaceutical Inc
Maruho Co Ltd
Mayly Life Sciences
Microbiotix Inc
Moderna Inc
NanoViricides Inc
Rational Vaccines Inc
Redbiotec AG
Safety Shot Inc
Savoy Pharmaceuticals Inc
Shanghai BDgene Therapeutics Co Ltd
Shulov Innovative Science Ltd
Sinopharm Zhongsheng Biotechnology Research Institute Co Ltd
Squarex Pharmaceutical Corp
Stealth Biologics LLC
Sunomix Therapeutics
SymBio Pharmaceuticals Ltd
The Chinese University of Hong Kong
The University of Manchester
Thyreos LLC
United BioPharma Inc
University of Pennsylvania
University of Wisconsin Madison
Vaxart Inc
Vaxxit Srl
Vectans Pharma SAS
Vir Biotechnology Inc
Viramatix Sdn Bhd
Vironika LLC
Vironova Medical AB
Virothera Ltd
Westmead Millennium Institute for Medical Research
X-Vax Technology Inc
Yaso Therapeutics Inc
Zhuhai Trinomab Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Simplexvirus (HSV) Infections reports